ArticleBioactive materials2020
Enhanced osteogenesis and therapy of osteoporosis using simvastatin loaded hybrid system.
Article in Bioactive materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Simvastatin and Moxifloxacin Co-Delivery via ZIF-8/PDA Coating on PEEK Implants: A Strategy for Combating Implant-Associated Infection and Enhancing Osseointegration.International journal of nanomedicine · 2026Article
- Mevalonate pathway-triggered phase transition of injectable hydrogel for cholesterol-downregulated therapy of osteoarthritis.Bioactive materials · 2025Article
- Accelerating Bone Healing With METTL3 Overexpressed Adipose-Derived Stem Cells in Osteoporotic Rats.Cell proliferation · 2025Article
- TGF-β1/BSA coating modulates multi-phasic scaffolds for osteochondral tissue regeneration.Materials today. Bio · 2025Article
- Nanotechnology in Orthopedic Care: Advances in Drug Delivery, Implants, and Biocompatibility Considerations.International journal of nanomedicine · 2025Review
- The Emerging Roles of Nano Drug Delivery Systems in Treatment of Osteoporosis-Current Knowledge, Challenges and Future Perspectives.International journal of nanomedicine · 2025Review
- Nanostructures in Orthopedics: Advancing Diagnostics, Targeted Therapies, and Tissue Regeneration.Materials (Basel, Switzerland) · 2024Review
- Low-molecular-weight estrogenic phytoprotein suppresses osteoporosis development through positive modulation of skeletal estrogen receptors.Bioactive materials · 2024Article
- Silver Nanoparticles and Simvastatin-Loaded PLGA-Coated Hydroxyapatite/Calcium Carbonate Scaffolds.Nanomaterials (Basel, Switzerland) · 2024Article
- Statins-Their Role in Bone Tissue Metabolism and Local Applications with Different Carriers.International journal of molecular sciences · 2024Review
- Cell-microsphere based living microhybrids for osteogenesis regulating to boosting biomineralization.Regenerative biomaterials · 2024Article
- Osteoporosis treatment: current drugs and future developments.Frontiers in pharmacology · 2024Review
- An update on the advances in the field of nanostructured drug delivery systems for a variety of orthopedic applications.Drug delivery · 2023Article
- Drug Delivery and Therapy Strategies for Osteoporosis Intervention.Molecules (Basel, Switzerland) · 2023Review
- Article
- Constructions of ROS-responsive titanium-hydroxyapatite implant for mesenchymal stem cell recruitment in peri-implant space and bone formation in osteoporosis microenvironment.Bioactive materials · 2022Article
- Poly(Gels (Basel, Switzerland) · 2022Review
- Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?International journal of molecular sciences · 2022Review
- The Mechanism of Bone Remodeling After Bone Aging.Clinical interventions in aging · 2022Review
- Advances in Use of Nanomaterials for Musculoskeletal Regeneration.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis is a common chronic dynamic bone disorder, caused by estrogen deficiency. To address this issue, we constructed a controlled drug-release system composed of poly (N-isopropylacrylamide) brush modified mesoporous hydroxyapatite (MHA-SIM-P) loaded with simvastatin (SIM) using an ovariectomised (OVX) rat model. Quantitative alkaline phosphatase activity assay, alizarin red staining and RT-PCR were tested to evaluate the osteogenic ability
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.